Related Experiment Video
Updated: Jan 17, 2026

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression
Published on: May 15, 2014
Predisposing Factors, Control Strategies, and Antiviral Therapy of Mpox Virus as a Potential Zoonotic Agent
Elham Zarenezhad1, Mahrokh Marzi1, Fattma A Ali2
1Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Abstract:
Background: Monkeypox (Mpox) virus is a virulent zoonotic agent and a member of Poxviridae family. Owing to environmental, social and behavioral factors, and lack of approved vaccines or antiviral agents, the eradication of Mpox has not been successful until today. Material and methods: This study overviewed published data to assess predisposing factors, control strategies and antiviral therapy of mpox virus. Results: The recent Mpox outbreak occurred due to human behavioral factors with a cumulative total of 91,123 laboratory-confirmed cases, including 157 deaths during March 2022-September 2023. Viral immunoregulatory proteins, such as vaccinia complement control protein, inflammation modulatory protein, smallpox inhibitor of complement enzymes, chemokine binding protein, and vaccinia virus growth factor, suppress efficient responses. Host genetic variations in IL1RN (interleukin 1 Receptor Antagonist, rs452204) and IL12RB2 (rs3790567) genes and interferon-α deficiency predispose the host to more severe Mpox infection. Conclusion: Combination therapy and drug repositioning include promising approaches for the efficient antiviral therapy. The worldwide collaboration is required to enhance outbreak preparedness and infection control.
Insights
Mpox virus, a zoonotic agent, has seen a resurgence due to behavioral factors. Combination therapy and drug repositioning show promise for antiviral treatment, requiring global collaboration for control.
Area of Science:
- Virology
- Immunology
- Epidemiology
Background:
- Monkeypox (Mpox) virus, a virulent zoonotic agent from the Poxviridae family, has proven difficult to eradicate.
- Lack of approved vaccines and antiviral agents, coupled with environmental, social, and behavioral factors, contribute to its persistence.
Purpose of the Study:
- To assess predisposing factors for Mpox infection.
- To review current control strategies for Mpox.
- To evaluate antiviral therapy options for Mpox virus.
Main Methods:
- Systematic review of published data on Mpox.
- Analysis of epidemiological data from March 2022 to September 2023.
- Examination of viral immunoregulatory proteins and host genetic factors.
Main Results:
- The recent Mpox outbreak involved over 91,000 cases and 157 deaths, linked to human behavioral factors.
- Viral proteins (e.g., vaccinia complement control protein) suppress host immune responses.
- Host genetic variations (IL1RN, IL12RB2) and interferon-α deficiency increase Mpox severity.
Conclusions:
- Combination therapy and drug repositioning are promising for effective Mpox antiviral treatment.
- Enhanced global collaboration is crucial for improved outbreak preparedness and infection control.
Related Concept Videos
Infection
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
Viral Recombination
Retrovirus Life Cycles
Retroviruses

